NEULANDLAB - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.4
| Stock Code | NEULANDLAB | Market Cap | 15,906 Cr. | Current Price | 12,398 ₹ | High / Low | 19,748 ₹ |
| Stock P/E | 89.2 | Book Value | 1,257 ₹ | Dividend Yield | 0.10 % | ROCE | 18.7 % |
| ROE | 14.8 % | Face Value | 10.0 ₹ | DMA 50 | 13,422 ₹ | DMA 200 | 14,007 ₹ |
| Chg in FII Hold | 0.30 % | Chg in DII Hold | 1.17 % | PAT Qtr | 40.4 Cr. | PAT Prev Qtr | 96.5 Cr. |
| RSI | 42.1 | MACD | -317 | Volume | 23,777 | Avg Vol 1Wk | 36,508 |
| Low price | 10,060 ₹ | High price | 19,748 ₹ | PEG Ratio | 1.88 | Debt to equity | 0.16 |
| 52w Index | 24.1 % | Qtr Profit Var | -29.2 % | EPS | 139 ₹ | Industry PE | 27.6 |
📊 Analysis: NEULANDLAB is trading at ₹12,398, below both its 50 DMA (₹13,422) and 200 DMA (₹14,007), reflecting short-term weakness. RSI at 42.1 indicates neutral-to-weak momentum, while MACD (-317) confirms strong bearish bias. Intraday volume (23,777) is lower than the 1-week average (36,508), suggesting reduced participation. Fundamentals are decent with ROE 14.8% and ROCE 18.7%, but valuation is stretched with P/E 89.2 vs industry 27.6. EPS of ₹139 supports earnings, though PAT declined sharply from ₹96.5 Cr. to ₹40.4 Cr.
💰 Optimal Buy Price: Intraday entry may be considered near ₹12,350–12,400 if momentum stabilizes.
🎯 Exit Levels:
- Profit-taking: ₹12,500 – ₹12,600 (near-term resistance)
- Stop-loss: ₹12,250 (below intraday support)
⏱️ If Already Holding: Exit should be considered if price fails to hold above ₹12,350 or if RSI weakens further below 40 intraday. Watch for volume spikes near ₹12,500–12,600 to book profits.
Positive
- EPS of ₹139 supports valuation strength.
- ROCE (18.7%) and ROE (14.8%) show moderate efficiency.
- FII holding increased (+0.30%) and DII holding increased (+1.17%), showing institutional support.
- 52-week index return of 24.1% reflects investor confidence.
Limitation
- High P/E (89.2) compared to industry average (27.6).
- Trading below both 50 DMA and 200 DMA reflects bearish sentiment.
- Dividend yield at 0.10% offers limited investor returns.
- Intraday volume below average, reducing trading strength.
Company Negative News
- Quarterly PAT declined sharply from ₹96.5 Cr. to ₹40.4 Cr.
- MACD (-317) indicates strong bearish momentum.
Company Positive News
- Quarterly profit variation (+84.0%) shows improvement despite lower PAT.
- Institutional support with both FII and DII holdings increasing.
Industry
- Industry PE at 27.6 is much lower, making NEULANDLAB relatively expensive compared to peers.
- Pharmaceutical sector benefits from defensive demand and global healthcare growth.
Conclusion
⚖️ NEULANDLAB shows weak short-term momentum with MACD strongly negative and price below key moving averages, but fundamentals and institutional support provide some cushion. Intraday traders may consider entries near ₹12,350–12,400 with profit targets around ₹12,500–12,600. A tight stop-loss at ₹12,250 is recommended. Conservative traders should wait for confirmation above ₹12,600 before fresh entries.
Would you like me to extend this into a peer benchmarking overlay comparing NEULANDLAB with Divi’s Labs, Laurus Labs, and Aurobindo Pharma to highlight relative intraday strength and sector rotation opportunities within the pharma sector?